Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Jaarverslag 2024 Download

Documenten

Annex IX Informatie Document (gedateerd 24 januari 2025)

Notering van nieuwe aandelen – Annex IX

Artikel 7:198 juncto artikelen 7:179 en 7:191 van het Wetboek van Vennootschappen en Verenigingen

Rapport van de Raad van Bestuur

Rapport van de Commissaris

Contact informatie

Investor Relations:

Email: IR@sequanamedical.com
Tel: +32 498 053579